Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Merck KGaA announce cancer drug collaboration

Pfizer and Merck KGaA announce cancer drug collaboration

19th November 2014

Pfizer has announced a new collaboration with Merck KGaA, focusing on the development of a new immuno-oncology agent.

The global strategic alliance will see the firms working to jointly develop and commercialise MSB0010718C, an investigational anti-PD-L1 antibody created by Merck KGaA as a potential treatment for multiple types of cancer.

Both companies will explore the therapeutic potential of the antibody as a single agent, as well as in various combinations with Pfizer's and Merck KGaA's portfolios of approved and investigational oncology therapies.

They will collaborate on up to 20 high priority immuno-oncology clinical development programmes expected to commence in 2015, including up to six phase II or III trials that could be pivotal for potential product registrations.

Albert Bourla, group president of Pfizer's vaccines, oncology and consumer healthcare businesses, said "This global alliance enables Pfizer and Merck KGaA to join forces and combine complementary strengths with the goal of meeting the needs of patients with multiple types of cancer."

The company has also formed new cancer-focused partnerships with Merck Sharp and Dohme and Kyowa Hakko Kirin in recent months.ADNFCR-8000103-ID-801761021-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.